TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32618438
Drug: Marketed 150
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed 150 mg peficitinib tablet
Study: 34749425
Drug: Intensive olfactory
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive olfactory training (IOT) - twice a day with a 40-odor set for 15 days
Study: 33116470
Drug: Systemic steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroid therapy administered to 658 patients (53%)
Study: 33116470
Drug: Non-steroid users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid users
Study: 34236951
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition of an occupational therapy driving intervention
Study: 32849284
Drug: Nutraceutical containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical containing Bergamot polyphenol fraction and Cynara Cardunculus extract, 300 mg/day for 12 weeks
Study: 35622972
Drug: Pacritinib (PAC)
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib (PAC) 400 mg daily in PERSIST-1
Study: 35622972
Drug: Pacritinib (PAC)
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib (PAC) 400 mg daily or 200 mg twice daily in PERSIST-2
Study: 35622972
Drug: Pacritinib (PAC)
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib (PAC) 200 mg twice daily in PAC203 study
Study: 34979178
Drug: Daily steps
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily steps (average 3,460 ± 1,768 steps per day)
Study: 35353553
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm assignment
Study: 35353553
Drug: Enrollment in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrollment in treatment arms
Study: 34310692
Drug: Rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 0.6 mg·kg-1
Study: 34310692
Drug: Remifentanil 2
Normalized name: remifentanil 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 2 µg·kg-1
Study: 35313351
Drug: Auditory naming-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory naming-related high gamma augmentation
Study: 35313351
Drug: Picture naming-related
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picture naming-related high gamma augmentation
Study: 35313351
Drug: Naming-related low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naming-related low gamma augmentation and alpha/beta attenuation
Study: 34433897
Drug: Bacillus pumilus
Normalized name: Bacillus pumilus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus pumilus inoculated seeds at 0.25 mg kg‐1 of CdSO4
Study: 34433897
Drug: Bacillus pumilus
Normalized name: Bacillus pumilus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus pumilus uninoculated seeds at 0.75 mg kg‐1 of CdSO4
Study: 35594778
Drug: e‐CBT‐I (internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐CBT‐I (internet-delivered cognitive-behavioral therapy for insomnia)
Study: 33532995
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg·kg−1 bolus before surgery, followed by 0.05 mg·kg−1·hr−1 infusion until end of surgery)
Study: 35270624
Drug: Acetaminophen (ACT)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (ACT) 500 mg, three caplets
Study: 35270624
Drug: Placebo (PLA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA), three gelatin capsules
Study: 36750617
Drug: First-line pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line pembrolizumab monotherapy
Study: 36401407
Drug: Sopoongsan (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sopoongsan (treatment group, n = 10)
Study: 35467095
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment in mCRPC patients
Study: 35467095
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment in mHSPC patients
Study: 34400961
Drug: Olanzapine (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (0.14 mg/kg)
Study: 32036964
Drug: CUR (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CUR (400 mg/kg curcumin)
Study: 32036964
Drug: OTA +
Normalized name: Otamixaban
DrugBank: Otamixaban (DB06635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTA + CUR (2 mg/kg OTA plus 400 mg/kg curcumin)
Study: 32036964
Drug: OTA (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OTA (2 mg/kg OTA)
Study: 35659763
Drug: Radiofrequency turbinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency turbinate reduction followed by intranasal steroid and Antihistamine H-1 (AH-1)
Study: 35659763
Drug: Intranasal steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal steroid and Antihistamine H-1 (AH-1)
Study: 35241426
Drug: deucravacitinib 6
Normalized name: deucravacitinib 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: deucravacitinib 6 mg once a day
Study: 35241426
Drug: deucravacitinib 12
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: deucravacitinib 12 mg once a day
Study: 33051119
Drug: NLP algorithms
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP algorithms for detecting implant model
Study: 32811464
Drug: Dance Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dance Group (DG) - Brazilian dance program inspired by Samba and Forró rhythms, 24 sessions of 1 hour each, twice per week for 12 weeks.
Study: 35763398
Drug: Socket shield
Normalized name: Peroxy Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socket shield technique with immediate implant placement in contact (Group A)
Study: 35763398
Drug: Socket shield
Normalized name: Peroxy Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socket shield technique with immediate implant placement leaving a gap (Group B)
Study: 36332653
Drug: Combination prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination prevention intervention with universal antiretroviral therapy (ART; arm A)
Study: 36438688
Drug: Camrelizumab (SHR‐1210)
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab (SHR‐1210) combined with gemcitabine plus cisplatin (GP) chemotherapy
Study: 37280275
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin (GP) chemotherapy
Study: 36212931
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (2 mg/kg bolus over 5 minutes, then 1.5 mg/kg/h infusion)
Study: 36212931
Drug: Dexamethasone (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.15 mg/kg over 5 minutes, followed by saline)
Study: 35999678
Drug: Intranasal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal fentanyl (1 μg/kg) combined with oral midazolam (0.7 mg/kg)
Study: 35999678
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.7 mg/kg) alone
Study: 34380301
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet (LCD), physical exercises in the gym, daily walking up to 3-5 km/day
Study: 34380301
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet (LCD), physical exercises in the gym, daily walking up to 3-5 km/day, nutraceutical correction
Study: 35749413
Drug: 12-week Tai
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week Tai Chi program (45 minutes per session, twice a week)
Study: 34873674
Drug: GSK2256294 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256294 (10 mg once daily for 10 days)
Study: 33629110
Drug: Anifrolumab 300
Normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab 300 mg every 4 weeks
Study: 35830070
Drug: Acaulospora longula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acaulospora longula treatments
Study: 35830070
Drug: G. albida
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. albida + Bradyrhizobium BR 3267
Study: 33528904
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg/day) with no meal announcement
Study: 33528904
Drug: Empagliflozin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (25 mg/day) with simple meal announcement
Study: 34981490
Drug: Lentil group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lentil group (500 mg of lentil powder daily for 3 months)
Study: 34981490
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (placebo daily for 3 months)
Study: 32503494
Drug: Trimetazidine (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (35 mg twice a day)
Study: 35729250
Drug: L-menthol (n=26)
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-menthol (n=26)
Study: 35729250
Drug: L-menthol
Normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-menthol
Study: 34250817
Drug: Liraglutide (glucagon-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (glucagon-like peptide-1 receptor agonist)
Study: 36036907
Drug: Lumbar epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar epidural steroid injections (LESIs)
Study: 36036907
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment in the RCT of LESI
Study: 35866910
Drug: Baricitinib in
Normalized name: Product containing baricitinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib in combination with topical corticosteroids
Study: 33200220
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg (+MTX)
Study: 33200220
Drug: Placebo (+MTX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (+MTX) switched to Baricitinib 4 mg (+MTX)
Study: 32811629
Drug: Take-home naloxone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home naloxone (THN) administration with positive communication
Study: 32811629
Drug: Take-home naloxone
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take-home naloxone (THN) administration with negative communication
Study: 34431970
Drug: IL-6 levels
Normalized name: IL-6
DrugBank: Human interleukin-6 (DB15060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-6 levels ≥2.0 ng/L
Study: 32749173
Drug: Oral EGCG
Normalized name: EGCG
DrugBank: Epigallocatechin gallate (DB12116)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral EGCG 100 mg twice daily for 10 days
Study: 33629114
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AIs) adherence
Study: 33262578
Drug: Evogliptin 5
Normalized name: alogliptin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evogliptin 5 mg alone (EVO)
Study: 33262578
Drug: Glimepiride 4
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride 4 mg alone (GLI)
Study: 33262578
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of evogliptin and glimepiride (EVO+GLI)
Study: 35622848
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) as an adjunct to standard of care with medical oxygen
Study: 34024187
Drug: Iodine excretion
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine excretion level in urine among school-aged children
Study: 34024187
Drug: Iodine excretion
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine excretion level in urine among pregnant women
Study: 36153475
Drug: Itacitinib (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib (a selective JAK1 inhibitor) combined with ASTX727 (a fixed dose oral combination of decitabine and cedazuridine)
Study: 32385845
Drug: 0.2% sirolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% sirolimus gel
Study: 34627832
Drug: Serratus anterior
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus anterior plane block (SAPB) with 0.4 mL.kg-1 0.5% ropivacaine
Study: 32359776
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg intravenous dexketoprofen trometamol
Study: 32359776
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dexketoprofen trometamol + 10 mg metoclopramide
Study: 32131911
Drug: CORDIAL program
Approvals — FDA: no, EMA: no, PMDA: no
Description: CORDIAL program (11 individual weekly sessions of CBT, cognitive rehabilitation, and reminiscence therapy)
Study: 32131911
Drug: Treatment-as-usual (Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (Control group)
Study: 34636493
Drug: Q-switched Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-switched Nd:YAG laser with daily 3% tranexamic acid gel
Study: 34636493
Drug: Microneedling with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedling with daily 3% tranexamic acid gel
Study: 32727548
Drug: Simparica Trio®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simparica Trio® (combination of sarolaner, moxidectin, and pyrantel)
Study: 34971551
Drug: KUR-113 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: KUR-113 (0.4 mg/mL)
Study: 34971551
Drug: KUR-113 (0.133
Approvals — FDA: no, EMA: no, PMDA: no
Description: KUR-113 (0.133 mg/mL)
Study: 34971551
Drug: KUR-113 (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: KUR-113 (1.0 mg/mL)
Study: 32168551
Drug: Palonosetron 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.75 mg (day 1) combined with dexamethasone and fosaprepitant
Study: 32168551
Drug: Granisetron 1
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 1 mg (day 1) combined with dexamethasone and fosaprepitant
Study: 35104166
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump infusion sets (various types)
Study: 35104166
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump infusion sets (90° Teflon)
Study: 35104166
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump infusion sets (angled Teflon)
Study: 35104166
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump infusion sets (steel)
Study: 35428722
Drug: SEC 300
Normalized name: sec-laureth-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEC 300 mg
Study: 35428722
Drug: SEC 150
Normalized name: sec-laureth-9
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEC 150 mg
Study: 32199095
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2 administered intravenously every week for 4 weeks, then 1000 mg every 2 weeks at 24 weeks and 48 weeks after randomisation)
Study: 32199095
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching intravenous administration)
Study: 35527576
Drug: Intensive computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive computer-based cognitive program using REHACOM software in addition to conventional physical therapy (aerobic training, resistive training, flexibility program)
Study: 35527576
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy program for MS including aerobic training, resistive training, flexibility program and placebo cognitive sessions
Study: 33001537
Drug: Topical TCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TCA 35%
Study: 36411567
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (risperidone 2‐6 mg/d, olanzapine 5‐20 mg/d, quetiapine 400‐750 mg/d, aripiprazole 10‐30 mg/d, ziprasidone 80‐160 mg/d)
Study: 36411567
Drug: Typical antipsychotics
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotics (perphenazine 20‐60 mg/d, haloperidol 6‐20 mg/d)
Study: 32744358
Drug: metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin + placebo
Study: 33279854
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg at day 1 of each cycle) and Tremelimumab (75 mg at day 1 for 4 cycles) - Arm A
Study: 33279854
Drug: Durvalumab, Tremelimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab, Tremelimumab with Paclitaxel (80 mg/m2 at D1, D8, D15) - Arm B
Study: 32609960
Drug: INP105 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: INP105 5 mg
Study: 32609960
Drug: INP105 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: INP105 10 mg
Study: 32609960
Drug: INP105 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: INP105 15 mg
Study: 32609960
Drug: OLZ IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ IM 5 mg
Study: 32609960
Drug: OLZ IM
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ IM 10 mg
Study: 32066609
Drug: Additional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional treatment
Study: 33180097
Drug: Fluvoxamine 100
Normalized name: fluvoxamine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine 100 mg, 3 times daily for 15 days
Study: 33180097
Drug: Placebo, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 3 times daily for 15 days
Study: 32116248
Drug: Learning Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning Therapy (LT), a combination of cognitive training and stimulation
Study: 32700396
Drug: Cilostazol 200
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 200 mg/d
Study: 32506275
Drug: Preoperative meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative meloxicam 15 mg at 24 h pre-operation, 7.5 mg at 4 h, 24 h, 48 h and 72 h post-operation
Study: 32506275
Drug: Postoperative meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative meloxicam 15 mg at 4 h post-operation, then 7.5 mg at 24 h, 48 h and 72 h post-operation
Study: 33285743
Drug: Afatinib monotherapy
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib monotherapy (20-40 mg)
Study: 33285743
Drug: Afatinib plus
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Afatinib plus HAD-B1 combination therapy (0.972 g/day for 48 weeks)
Study: 33850467
Drug: Multidisciplinary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary treatment
Study: 32544356
Drug: No pre‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre‐treatment (Group 3, n=12)
Study: 32390113
Drug: Upfront autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upfront autologous hematopoietic stem cell transplantation (ASCT) following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy
Study: 34818873
Drug: BT200 (0.18-48
Approvals — FDA: no, EMA: no, PMDA: no
Description: BT200 (0.18-48 mg) subcutaneously
Study: 35238750
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg pegloticase every 2 weeks (q2w)
Study: 35238750
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg pegloticase every 4 weeks (q4w)
Study: 36856614
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg once daily
Study: 34613954
Drug: Gluten challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten challenges (0, 10, 50, 100, 500, and 1,000 mg) during study A
Study: 34613954
Drug: Gluten challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluten challenge with 5 or 10 mg gluten during study B
Study: 32543258
Drug: Immediate maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate maintenance pemetrexed therapy
Study: 33225965
Drug: Anakinra (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (300 mg daily)
Study: 36233636
Drug: Denneroll cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denneroll cervical traction orthotic + TENS therapy + hot packs
Study: 36233636
Drug: TENS therapy
Normalized name: Walgreens Electronic TENS Therapy Pain Relief Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: TENS therapy + hot packs
Study: 34836149
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE; containing 500 mg epigallocatechin-3-gallate)
Study: 34117622
Drug: Early total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early total enteral nutrition (80 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Study: 34117622
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (30 mL/kg/d starting on day 1, advanced by 20 mL/kg/d)
Study: 38754459
Drug: Doxycycline 100
Normalized name: doxycycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 100 mg daily for 6 weeks
Study: 35871814
Drug: Abrocitinib 200
Normalized name: abrocitinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrocitinib 200 mg per day
Study: 32150215
Drug: 6-month structured
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month structured physical activity with or without a protein and vitamin D nutritional supplement